A Phase 1 theranostic radiopharmaceutical study entered execution with two investigational products, an evolving FDA expectation around intensive imaging, and a sponsor that had built a strong scientific program without the operational scaffolding underneath it. Progress required site-level radiopharm expertise, structured cross-functional integration, and a willingness to push back on the sponsor when experience warranted it.